Archive for the ‘NIH grant innovation’ Tag

New Webinar: NIH Submission Strategies — Register Now!

You have a cool idea for a research project, now what? The second in my new webinar series addresses NIH Submission Strategies. As a person who works on NIH submissions full time, I know there are certain steps you can take before you write a single word that correlate with better scores and outcomes.

Some of these steps include the following: taking the time to understand the priorities of the stakeholders involved, including reading Appropriations Reports; learning which projects are already in the NIH funding portfolio to ascertain how you might adjust your idea to fit in; identifying multiple ICs (not just an obvious one) and shopping around different versions of your Specific Aims to gauge enthusiasm; building a relationship with the all-important Program Officer, who will help guide questions related to study design, FOA, ESI status, and study section; and understanding the review process and audience before you write.

Your team will invest hundreds of hours in your submission. Why not spend 90 minutes learning some tried-and-true strategies to use before you write that will optimize your chance of success? I probably work on more NIH submissions in a month than you will work on across your entire career. I’ve helped clients land over $200 million in federal funds, and I can help strengthen your submission and improve your grantsmanship as well.

REGISTER FOR ALL 3 WEBINARS AND SAVE!
Bundle with two more webinars and save! Three webinars for $499.

Read about all three webinars, including “Mistakes Commonly Made on NIH Grant Applications” and “How To Write The Specific Aims.”

NIH Submission Strategies

Who: Essential for grantees planning to submit an R01, R21, or R03 in an upcoming cycle, and the senior faculty and administrators who advise them.
When: Wednesday 11 February 2015, 11am-12:30pm EST or
Thursday 19 February 2015, 11am-12:30pm EST
Cost: $199; Or register for all three webinars this month for $499
Takeaways: At the end of this 90-minute session, participants will be able to:

1. Utilize the Reporter website to identify their niche in the funding portfolio
2. Identify likely ICs, POs, and FOAs
3. Write several drafts of their Aims to send to POs
4. Choose the most appropriate IC, FOA, and study section with PO guidance

REGISTER NOW!

Posted February 5, 2015 by Meg Bouvier in Freelance medical writing, medical grant writing, NIH grantwriting

Tagged with , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Top Ten Things NIH Reviewers Should NOT Say In A Review

ID-10046929

Credit: Ambro at FreeDigitalPhotos.net

The Center for Scientific Review publishes their Peer Review Notes three times a year, and the most recent issue came out yesterday. The news items are always interesting and it is worth subscribing, if you don’t already. This issue contained an item about things NIH reviewers should not say. I repeat the list in its entirety here—I thought it might be fun for my grantees to see reviewers critiqued for a change.

What do you think of this list? Have you seen one or two of these on your Summary Statements? Me personally? I have seen variations on # 2, 4, and 10 in Summary Statements, and have strongly suspected reviewers of #1 and 5. I almost fell out of my chair laughing when I read # 7, sometimes I think CSR is a little out of touch with what actually happens on Study Sections:

  1. “I didn’t read the application, but I scanned it and saw the applicant said XXX. He doesn’t know what he’s doing.” Damning statements like this can skew a review discussion over something that might be insignificant in the context of the overall application. It’s better for you to ask other reviewers who have read the application carefully what they think about XXX.
  2. “This New Investigator does not appear to be fully independent since he continues to co-publish with his fellowship mentor/department chair, or does not have designated lab space, or has not been promoted in the past several years.”  Academic research organizations have widely diverse policies for faculty advancements and lab space, and many PIs maintain productive and healthy collaborations with mentors for many years after establishing themselves as bona fide investigators. You should focus more on the investigator accomplishments, such as being the first or senior author on a significant publication or giving presentations at major scientific meetings.
  3. “This application is not in my area of expertise . . . “  If you’re assigned an application you feel uncomfortable reviewing, you should tell your Scientific Review Officer as soon as possible before the meeting.
  4. “I don’t see this basic science research affecting my clinical practice any time soon.” An application does not necessarily have to show the potential for clinical or timely impact—if the applicant doesn’t make such claims. Basic research often takes time to pay off, and you’re charged to assess the “likelihood for the project to exert a sustained, powerful influence on the research field(s) involved.” Absence of an effect on public health does not necessarily constitute a weakness in basic science.
  5. “I like this project but I’m giving it a poorer score because the applicant has too much money.” Other funding is not a scoreable matter. You should focus on the application’s scientific and technical merit. However, you can note an excessive budget request in the budget section for NIH to consider.
  6. “This application has 2 great aims and 1 bad one. I would recommend deleting Aim 3, and I can give it a 1 or 2.” You cannot trade aims with scores. The application needs to be evaluated as a whole.
  7. “This R21 application does not have pilot data, which should be provided to ensure the success of the project.” R21s are exploratory projects to collect pilot data. Preliminary data are not required, although they can be evaluated if provided.
  8. “The human subject protection section does not spell out the specifics, but they already got the IRB approval, and therefore, it is ok.” IRB approval is not required at this stage, and it should not be considered to replace evaluation of the protection plans.
  9. “This application was scored a 25 and 14th percentile last time it was reviewed . . . .” You should not mention the previous score an application got, because this could skew the review discussion. Focus on the strengths and weaknesses of the current application as well as the responses to previous critiques.
  10. “This is a fishing expedition.” It would be better if you said the research plan is exploratory in nature, which may be a great thing to do if there are compelling reasons to explore a specific area. Well-designed exploratory or discovery research can provide a wealth of knowledge.

Dr. Bouvier Interviewed on Grantsmanship for the Journal Nature

We invite you to read Dr. Bouvier’s comments on grantsmanship in an article in the latest issue of the journal Nature.

The article, entitled, “Impact: Pack a Punch”, discusses the importance of impact in proposed research projects. It included comments from scientists and funding agency administrators from a wide variety of scientific fields in numerous countries. Dr. Bouvier was the only professional grantwriter who participated in the article.

Nature, a prominent international journal published weekly, remains one of the few journals to publish research spanning all of the scientific disciplines. It is one of the most widely cited journals in science worldwide.

Dr. Bouvier provided permission for her information to be translated for their Japanese and Arabic editions.

Posted October 21, 2013 by Meg Bouvier in Biomedical research, Freelance medical writing, medical grant writing, medical policy writing, NIH grantwriting

Tagged with , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

The Importance of the “Approach” Criterion On NIH Grant Scores

Sally Rockey, Deputy Director of Extramural Research at NIH, posted data on her blog concerning reviewer behavior on proposals reviewed in 2010. Recall that with the new NIH grant format, NIH implemented scores of one to five (lower is better) in each of five categories: Significance, Innovation, Approach, Investigators, and Environment, as well as the overall impact score. Of 54,727 applications reviewed in FY10, 32,546 were discussed and received overall impact scores. The NIH generated some data on these scores. Among their findings:

*While reviewers used the full scoring range (one through five) for each of the five review categories, their scores were distributed more widely for the Approach category.

*Criterion scores are moderately correlated with each other and with the overall impact score.

*Of the five scoring categories, the one best able to predict the overall impact score was the Approach section (followed by significance, innovation, investigators, environment.)

The language surrounding the changes to the NIH grant format in Zerhouni’s efforts to enhance peer review stressed the importance of Impact, Significance, and Innovation. And in the new format, the length of the Research Strategies was halved, forcing grantees to compress “Approach” sections such as the exhaustive literature review and the detailed methodologies. However, from the data in Rockey’s blog post, we might surmise that reviewers still heavily weigh the Approach category. And based on my own experience with pink sheets in the new format, reviewers’ nearly-insatiable desire for preliminary data appears to continue unabated, despite the reduced page limits on proposals.

Multiple Regression To Predict Impact Scores Using Criterion Scores

Criterion Regression Weight
Approach

6.7

Significance

3.3

Innovation

1.4

Investigator

1.3

Environment

-0.1

How To Write an NIH Grant in the “New” Format

I put “new” in quotes because the revised NIH grant format went into effect last January, 2010. We are now into our fourth grant cycle with this format. In addition, we have seen pink sheets for two of those cycles, so we know what’s getting funded, what isn’t, what reviewers love and what they hate. I still get asked all the time about the new NIH grant format—it’s the most common question after funding rates (see blog entry from January 10.) So what do you need to know as you embark upon writing an NIH grant in the new format?

It’s all about impact. If you remember nothing else, please remember to emphasize the impact of your work. Remember the NIH mission statement: to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability. Make sure the reviewers are abundantly clear how your work will reduce human suffering or improve health. Talk about it in the Summary, in the Specific Aims, and in the Significance section. Highlight it with formatting (bold, italics, underline—but please only one of these, not all three!)

The format aligns with the review criteria. Yea! It seems like a no-brainer that the two ought to be parallel. But the old format was not aligned with the review criteria. What are the review criteria, you ask?

1. Significance . Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge or clinical practice be advanced? What will be the effect of these studies on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

2. Approach . Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?

3. Innovation . Is the project original and innovative? For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?

4. Investigators . Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers? Does the investigative team bring complementary and integrated expertise to the project (if applicable)?

5. Environment . Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support?

Less real estate. The page length has been halved in the new format: R01s are 12 pages and R03s and R21s are a mere six pages. That means you need to get to the point. This shorter page limit together with the switch to only one resubmission means that you have fewer opportunities to be convincing. But one’s best, most persuasive writing ought to be brief anyway.

Lose the exhaustive literature review. One of the casualties of the shorter format is the lengthy lit review. Save that for your publications.

Ditto the extensive experimental detail. You simply do not have enough space in a 12-page R01 to go on at length about every single solitary detail concerning your methods. Save that for your publications.

Publish in peer-reviewed journals as much as humanly possible. Given the two aforementioned items, one can see that it is now more important than ever to publish in peer-reviewed journals. To a certain extent, you need to demonstrate your grasp of the literature and your experimental expertise in peer-reviewed journals rather than in NIH proposals. For these reasons, I feel the new format favors established investigators over newbies.

Write carefully the narrative overview in the biosketch. That’s right: your NIH biosketch no longer can sit in an obscure file on your computer desktop, ready to be dusted off when you submit a proposal. Now you must write the four-page biosketch anew with each submission. Of particular importance is the brief personal statement in the beginning, where you state how you are uniquely qualified to contribute to this particular project; and the publications, which are limited to 15 and must be chosen to reflect your qualifications for this particular project.

Choose your mentor(s) carefully. If you are a newbie with few publications, it is critically important that you choose a stellar mentor(s). If you are not writing a mentored (K-series) proposal, be sure to bring someone more experienced on as a consultant or key personnel, but not as a multi-PI, or their credentials will eclipse yours and defeat the purpose of writing your own R-series grant. Choose someone with an extensive publication list in solid peer-reviewed journals. Preferably, the person will have a track-record of landing grants at the NIH institute to which you are applying. This mentor’s endorsement of you as a new investigator serves in essence as another type of “peer review” in the eyes of the reviewers.

Still feel overwhelmed and confused? You can always hire yourself an experienced grantwriter!

%d bloggers like this: